Target and Its Patented Drug(s)

Content Navigation (  All   None )                                      
Target General Information
Patent(s) and the Corresponding Patented Drug(s)
References
Target General Information  Top
Target ID T83145 Target Info
Target Name Nuclear factor NF-kappa-B (NFKB)
Synonyms Nuclear factor of kappa light polypeptide gene enhancer in B-cells; DNA-binding factor KBF
Target Type Successful Target
Gene Name NFKB1; NFKB2; RELA; RELB; REL
UniProt ID
NFKB1_HUMAN; NFKB2_HUMAN; TF65_HUMAN; RELB_HUMAN; REL_HUMAN
Patent(s) and the Corresponding Patented Drug(s)  Top
World Intellectual Property Organization (WIPO)
Patent ID WO2013082253
Title Non-Hormonal Steroid Modulators of Nf-Kb for Treatment of Disease.
Abstract The present invention relates to compounds and methods which may be useful as treatments of diseases.
Applicant(s) Reveragen Biopharma, Inc
Representative Drug(s) D02CEY Drug Info N.A. Click to Show More [1]
2 D05CGR Drug Info N.A. [1]
3 D0K0TL Drug Info N.A. [1]
4 D0PB2J Drug Info N.A. [1]
Patent ID WO2012071414
Title Quinoxaline Compounds and Uses Thereof.
Abstract Disclosed herein are compounds of formula (I) and methods of inhibiting IKKbeta and the NF-kappaB signaling and mTOR pathways.
Applicant(s) Board of Regents of the University of Nebraska
Representative Drug(s) D05WCW Drug Info N.A. Click to Show More [1]
2 D08YMD Drug Info N.A. [1]
3 D0XQ5E Drug Info N.A. [1]
Patent ID WO2011127048
Title Non-Hormonal Steroid Modulators of Nf-kappab for Treatment of Disease.
Abstract The present invention relates to compounds and methods which may be useful as treatments of neuromuscular diseases such as muscular dystrophy, and as inhibitors of NF-kappa for the treatment or prevention of muscular wasting disease, including muscular dystrophy.
Applicant(s) Validus Biopharma
Representative Drug(s) D02WOW Drug Info N.A. Click to Show More [1]
2 D08RUK Drug Info N.A. [1]
3 D09OGV Drug Info N.A. [1]
4 D0P0KY Drug Info N.A. [1]
Patent ID WO2012148247
Title Pharmaceutical Composition Containing Oleanolic Acid Acetate As An Active Ingredient for Preventing or Treating Tlr- or Il-6-Mediated Diseases.
Abstract The present invention relates to a pharmaceutical composition for preventing or treating TLR- or IL-6-mediated diseases, containing oleanolic acid acetate or pharmaceutically acceptable salts thereof.
Applicant(s) Korea Research Institute of Bioscience and Biotechnology
Representative Drug(s) D0KO3I Drug Info N.A. [1]
Patent ID WO2012060594
Title Anti-Inflammatory Composition Containing A Thiourea Compound and A Pharmaceutically Acceptable Salt Thereof As An Active Ingredient.
Abstract The present invention relates to a pharmaceutical composition for preventing or treating inflammatory diseases, wherein the pharmaceutical composition contains, as an active ingredient, a t.
Applicant(s) Chonbuk National University Industrial Cooperation Foundation
Representative Drug(s) D04NKE Drug Info N.A. [1]
Patent ID WO2011152671
Title Pharmaceutical Composition for The Prevention or Treatment of Inflammatory Diseases or Immune Diseases Containing Ramalin.
Abstract The present invention relates to anti-inflammatory activity which constitutes a novel use for ramalin isolated from the Antarctic lichen Ramalina terebrata, and more specifically relates to a pharmace.
Applicant(s) Korea Ocean Research and Development Institute
Representative Drug(s) D01LTK Drug Info N.A. [1]
Patent ID WO2009074809
Title Sigma Ligands and Ikk / Nf - Kb Inhibitors for Medical Treatment.
Abstract The present invention relates to agents that act in concert with sigma receptor ligands to enhance their effectiveness in the treatment of cancer and inflammatory disease. It also relates to methods whereby agents can be identified that will be of use in combination with sigma ligands in the treatment of the aforesaid diseases.
Applicant(s) University of Dundee
United States Patent and Trademark Office (USPTO)
Patent ID US20140073668
Title N-Quinolin-Benzensulfonamides and Related Compounds for The Treatment of Cancer, Autoimmune Disorders and Inflammation.
Representative Drug(s) D03WHA Drug Info N.A. Click to Show More [1]
2 D04GMP Drug Info N.A. [1]
3 D0X2ZY Drug Info N.A. [1]
Patent ID US20138552206
Title Nf-Kappab Inhibitors and Uses Thereof.
Representative Drug(s) D0D6DE Drug Info N.A. Click to Show More [1]
2 D0R4RV Drug Info N.A. [1]
Patent ID US20130289041
Title Quinoxaline Compounds and Uses Thereof.
Representative Drug(s) D09VXA Drug Info N.A. Click to Show More [1]
2 D0O5TC Drug Info N.A. [1]
3 D0Q6JK Drug Info N.A. [1]
Patent ID US20130116324
Title Pharmaceutical Composition for The Prevention or Treatment of Inflammatory Diseases or Immune Diseases Containing Ramalin.
Applicant(s) Korea Ocean Research and Development Institute
Representative Drug(s) D0ED5S Drug Info N.A. [1]
Patent ID US20140005276
Title Topical Application of 1-Hydroxyl-3,5-Bis(4Hydroxyl Styryl)Benzene.
Representative Drug(s) D06YEK Drug Info N.A. [1]
Patent ID US20140005275
Title Topical Application of 1-Hydroxyl-3,5-Bis(4Hydroxyl Styryl)Benzene.
Representative Drug(s) D00THJ Drug Info N.A. [1]
Patent ID US20140004068
Title Topical Application of 1-Hydroxyl-3,5-Bis(4Hydroxyl Styryl)Benzene.
Representative Drug(s) D0J2VS Drug Info N.A. [1]
Patent ID US20140004066
Title Topical Application of 1-Hydroxyl-3,5-Bis(4Hydroxyl Styryl)Benzene.
Representative Drug(s) D05UGL Drug Info N.A. [1]
Patent ID US20138524747
Title Pharmaceutical Compositions.
Patent ID US20128324401
Title Indane Modulators of Glucocorticoid Receptor, Ap-1, and/or Nf-Kappab Activity and Use Thereof.
Representative Drug(s) D0F5TR Drug Info N.A. [1]
Patent ID US20128304539
Title Fused Heteroaryl Modulators of Glucocorticoid Receptor, Ap-1, and/or Nf-Kappab Activity and Use Thereof.
Representative Drug(s) D04NMJ Drug Info N.A. [1]
Patent ID US20128207151
Title Non-Hormonal Steroid Modulators of Nf-Kappab for Treatment of Disease.
Representative Drug(s) D08NGV Drug Info N.A. [1]
Patent ID US20128198311
Title Modulators of Glucocorticoid Receptor, Ap-1, and/or Nf-Kappab Activity and Use Thereof.
Representative Drug(s) D0Q5YJ Drug Info N.A. [1]
Patent ID US20128106046
Title Cyclopentathiophene Modulators of The Glucocorticoid Receptor, Ap-1, and/or Nf-Kappab Activity and Use Thereof.
Representative Drug(s) D0LT6Z Drug Info N.A. [1]
Patent ID US20118067447
Title Modulators of Glucocorticoid Receptor, Ap-1, and/or Nf-Kappab Activity and Use Thereof.
Representative Drug(s) D0F9GL Drug Info N.A. [1]
Patent ID US20118034940
Title Modulators of Glucocorticoid Receptor, Ap-1, and/or Nf-Kappab Activity and Use Thereof.
Representative Drug(s) D0GN7U Drug Info N.A. [1]
Patent ID US20118013004
Title Modulators of The Glucocorticoid Receptor, Ap-1, and/or Nf-Kappab Activity and Use Thereof.
Representative Drug(s) D0DL3R Drug Info N.A. [1]
Patent ID US20117994190
Title Modulators of Glucocorticoid Receptor, Ap-1, and/or Nf-Kappab Activity and Use Thereof.
Representative Drug(s) D0BL3X Drug Info N.A. [1]
Patent ID US20117968577
Title Modulators of Glucocorticoid Receptor, Ap-1, and/or Nf-Kappab Activity and Use Thereof.
Representative Drug(s) D0BQ8A Drug Info N.A. [1]
Patent ID US20117888381
Title Modulators of Glucocorticoid Receptor, Ap-1, and/or Nf-Kappab Activity, and Use Thereof.
Representative Drug(s) D0Y2RN Drug Info N.A. [1]
Patent ID US20110213001
Title Pharmaceutical Compositions.
Patent ID US20110151022
Title Thiotungstate Analogues and Uses Thereof.
Representative Drug(s) D0OY0Q Drug Info N.A. [1]
Patent ID US20110002952
Title Fused Heteroaryl Modulators of Glucocorticoid Receptor, Ap-1, and/or Nf-Kappab Activity and Use Thereof.
Representative Drug(s) D0E7ZN Drug Info N.A. [1]
European Patent Office (EPO)
Patent ID EP20132578214
Title Pharmaceutical Composition for The Prevention or Treatment of Inflammatory Diseases or Immune Diseases Containing Ramalin.
Applicant(s) Korea Ocean Research and Development Institute
Representative Drug(s) D07NCJ Drug Info N.A. [1]
Patent ID EP20112308842
Title Pharmaceutical Compositions.
References  Top
REF 1 Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34.
REF 2 Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.